Elizabeth Plimack, MD, MS, FASCO

Elizabeth Plimack, MD, MS, FASCO, is the Deputy Director of Fox Chase Cancer Center.

Articles by Elizabeth Plimack, MD, MS, FASCO

Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
View More
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
Brian Rini, MD, FASCORoundtable | February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
Brian Rini, MD, FASCORoundtable | February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Elizabeth Plimack, MD, MS, FASCOASCO GU Symposium 2024 | January 30, 2024
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | December 19, 2023
Dr. Plimack provides a summary of her presentation at the SUO Annual Meeting on the progress of ADCs in UC research.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Brian Rini, MD, FASCOVideo Insights | August 23, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | April 24, 2023
Dr. Plimack discusses the results of her phase 2 study on hypomethylating agents, and gives a preview of research to come.
Elizabeth Plimack, MD, MS, FASCOAdvanced Urothelial Carcinoma | April 24, 2023
Elizabeth Plimack, MD, MS, provides an overview of a recent phase 2 trial of guadecitabine plus atezolizumab for mUC.